An example is the development of immunogenic exosomes (imsEVs) carrying mRNA for IFN-γ and presenting anti-CD71 and anti-PD-L1 antibodies on their surface, which have demonstrated anti-tumor efficacy even against tumors resistant to immunotherapy [45]. This evidence concerns the gene TFRC and neoplasm.